The Evolving Role of TKIs in First-line Treatment of Advanced HCC - a podcast by Clinical Care Options

In this podcast episode from Clinical Care Options (CCO), Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss first-line treatment of patients with advanced hepatocellular carcinoma. Topics include:

• Atezolizumab plus bevacizumab as the current standard of care
• Contraindications to atezolizumab plus bevacizumab
• The current role of tyrosine kinase inhibitors in first-line treatment of advanced hepatocellular carcinoma
• Ongoing clinical trials in the first-line setting

Presenters:  

Josep M. Llovet, MD, PhD, FAASLD
Professor of Medicine
Director, Mount Sinai Liver Cancer Program
Division of Liver Diseases
Mount Sinai School of Medicine
New York, NY
Professor of Research
Liver Unit, IDIBAPS
Hospital Clinic Barcelona
Barcelona, Spain

Univ. Prof. Markus Peck-Radosavljevic, MD, MBA
Professor of Medicine, Medical University of Vienna
Vienna, Austria
Department Chair, Innere Medizin and Gastroenterologie
Klinikum Klagenfurt am Wörthersee
Klagenfurt am Wörthersee, Austria

Link to full program, including accompanying downloadable slidesets:
https://bit.ly/2ZL9bxq

Further episodes of CCO Oncology Podcast

Further podcasts by Clinical Care Options

Website of Clinical Care Options